Inhibikase Therapeutics (IKT) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 26, 2026, to be held virtually for stockholders of record as of April 27, 2026.

• Proxy materials, including the notice, proxy statement, and annual report or Form 10-K, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting: Arvind Kush and Dennis Berman.

• Ratification of CohnReznick LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Amendment to certificate of incorporation to limit liability of certain officers as permitted by Delaware law.

• Amendment to 2020 Equity Incentive Plan to increase authorized shares by 3,000,000.

• Advisory vote on executive compensation and on the frequency of future advisory votes on executive compensation.

Board of directors and corporate governance

• Board recommends voting for all director nominees and all proposals, including a one-year frequency for future say-on-pay votes.